Man Group
KYTX icon

Man Group’s Kyverna Therapeutics KYTX Stock Holding History

Man Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Buy
68,640
+15,097
+28% +$134K ﹤0.01% 2002
2026
Q1 		$462K Buy
+53,543
New +$446K ﹤0.01% 2108

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Man Group's KYTX Position: Q2 2026 in Review

Man Group increased its Kyverna Therapeutics (KYTX) stake by 28% in Q2 2026, buying an estimated $134K and bringing the position to 68,640 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

Man Group first reported a position in KYTX in Q1 2026 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Man Group held 68,640 shares of Kyverna Therapeutics worth $612K as of Q2 2026.
  • Man Group bought 15,097 Kyverna Therapeutics shares in Q2 2026, an estimated $134K.
  • Kyverna Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2002 holding.
  • Man Group first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.